Product nameADAR1 overexpression 293T lysate (whole cell)
See all ADAR1 lysates
ab94050 is a 293T cell transfected lysate in which Human ADAR1 has been transiently over-expressed using a pCMV-ADAR1 plasmid. The lysate is provided in 1X Sample Buffer. Note: For more detailes about how the transfected lysate was prepared view preparation notes
Tested applicationsSuitable for: WBmore details
Storage instructionsShipped on dry ice. Upon delivery aliquot and store at -20ºC. Avoid freeze / thaw cycles.
Storage bufferConstituents: 0.01% Bromophenol blue, 2.3% Beta mercaptoethanol, 2% Sodium lauryl sulfate, 0.788% Tris HCl, 10% Glycerol (glycerin, glycerine)
Concentration information loading...
BackgroundFunction: Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA substrates without apparent sequence specificity. Has been found to modify more frequently adenosines in AU-rich regions, probably due to the relative ease of melting A/U base pairs as compared to G/C pairs. Functions to modify viral RNA genomes and may be responsible for hypermutation of certain negative-stranded viruses. Edits the messenger RNAs for glutamate receptor (GLUR) subunits by site-selective adenosine deamination. Produces low-level editing at the GLUR-B Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Binds to short interfering RNAs (siRNA) without editing them and suppresses siRNA-mediated RNA interference. Binds to ILF3/NF90 and up-regulates ILF3-mediated gene expression. Tissue specificity: Ubiquitously expressed, highest levels were found in brain and lung. Disease: Defects in ADAR are a cause of dyschromatosis symmetrical hereditaria (DSH) [MIM:127400]; also known as reticulate acropigmentation of Dohi. DSH is a pigmentary genodermatosis of autosomal dominant inheritance characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the dorsal parts of the hands and feet. Similarity: Contains 1 A to I editase domain. Contains 2 DRADA repeats. Contains 3 DRBM (double-stranded RNA-binding) domains. PTM: Sumoylation reduces RNA-editing activity.
Our Abpromise guarantee covers the use of ab94050 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent dilution.|
ab94050 at 15µg/lane on an SDS-PAGE gel.
All lanes : Anti-ADAR1 antibody (ab88574) at 1/500 dilution
Lane 1 :
ADAR1 overexpression 293T lysate (whole cell) (ab94050)
Lane 2 : 293T non-transfected lysate
Lysates/proteins at 25 µg per lane.
All lanes : Goat Anti-mouse IgG (H and L) HRP conjugated at 1/2500 dilution
ab94050 has not yet been referenced specifically in any publications.